
News|Articles|April 4, 2024
Is 2024 the Year for Psychedelic Medicine?
Author(s)Ashley Gallagher, Editor
MDMA-assisted therapy and psilocybin currently lead the way with potential approvals by the FDA.
Advertisement
Advertisement
Psychedelic therapy might be closer to reality than previously thought, with big movements in 2024 for midomafetamine capsules (MDMA)-assisted therapy and a separate adjunct treatment with psilocybin for mental health disorders. MDMA-assisted therapy from Lykos Therapeutics is being evaluated in combination with psychological interventions, which include psychotherapy and other services from a health care provider, for posttraumatic stress disorder (PTSD). CYB003 (Cybin), a psilocybin compound, is being evaluated as an adjunctive treatment for major depressive disorder.1,2
Related to this article

Pharmacists can help identify uncontrolled risk factors, review medications, and reinforce when patients should seek emergency care.

From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.

An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.

OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.

The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Advertisement
Advertisement



